Tag: Obstructive Sleep Apnea (OSA)
Sleep apnea patients on CPAP therapy live longer, study finds
March 19, 2025HME News Staff
SAN DIEGO – CPAP therapy significantly reduces the risk of death for people with obstructive sleep apnea, according to a landmark meta-analysis supported by Resmed and published in The Lancet Respiratory Medicine.
The study, which analyzed data from more than 1 million sleep apnea patients worldwide across 30 studies, found those on CPAP therapy have:
A 37% lower risk of dying from any cause compared to those with OSA who do not use CPAP.
A 55% lower risk of dying...
Rotech to supply CPAP alternative
November 26, 2024HME News Staff
ORLANDO, Fla. – Rotech Healthcare has announced a supplier agreement with Signifier Medical Technologies to introduce the eXciteOSA device to payers, health care providers and patients to treat mild to moderate obstructive sleep apnea.
The eXciteOSA device, approved by the U.S. Food and Drug Administration, uses neuromuscular electrical stimulation to tone tongue muscles to maintain an open airway during sleep, improving sleep quality and overall health.
“Partnering...
Inspire Medical Systems gets green light for V
August 5, 2024HME News Staff
MINNEAPOLIS – Inspire Medical Systems has announced approval from the U.S. Food and Drug Administration for the Inspire V therapy system, which includes a next generation neurostimulator for the treatment of obstructive sleep apnea. The system also includes the associated Bluetooth patient remote and physician programmer. “We are thrilled to announce the FDA approval of our next generation Inspire neurostimulation system,” said Tim Herbert, chairman and CEO of Inspire Medical Systems....
sovaSage promotes Caputo
July 8, 2024HME News Staff
PITTSBURGH – sovaSage, a company specializing in AI-based software and services for the management of obstructive sleep apnea, has promoted Jamie Caputo to vice president of sales. Caputo has played a key role in driving the roll out of two products: an AI-based software platform designed to select and fit the best CPAP mask for patients; and TherapistAssist Jeanie, a virtual sleep coach and compliance management platform that’s augmented with live support sleep coaches and respiratory...
Eli Lilly says tirzepatide reduces OSA severity
June 24, 2024HME News Staff
INDIANAPOLIS – Eli Lilly’s tirzepatide demonstrated a mean reduction of up to 62.8% on the apnea-hypopnea index (AHI), or about 30 fewer events restricting or blocking a person's airflow per hour of sleep, compared to placebo, according to the company’s SURMOUNT-OSA phase 3 clinical trials evaluating the drug for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity, with and without CPAP therapy.
In a key secondary endpoint, the company...
Mount Sinai 'poised to shift paradigm’ on sleep testing, therapy
February 13, 2024HME News Staff
NEW YORK – Mount Sinai researchers have been awarded a five-year, $4.1 million grant from the National Heart, Lung and Blood Institute at the National Institutes of Health to develop and study an artificial intelligence-powered model that predicts adverse outcomes of obstructive sleep apnea. Researchers say their model will better reflect the underlying physiology of the condition and the ways it impairs sleep, improving patient care and treatment. “Our proposal uses a state-of-the-art,...
Apnimed makes critical additions to C-suite
January 22, 2024HME News Staff
CAMBRIDGE, Mass. – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacological therapies for the treatment of obstructive sleep apnea and related disorders, has named Graham Goodrich as chief commercial officer and Ted Harding as chief human resources officer. The company says the additions to the C-suite are critical as the company prepares to launch AD109, a potential nighttime oral treatment currently in Phase 3. “We are thrilled to have attracted two...
Dr. Paruthi on thoughtful approach to trackers
December 20, 2023Theresa Flaherty, Managing Editor
YARMOUTH, Maine – Using health trackers to monitor sleep has become almost as common as using them to count steps, but they can be limited, especially when it comes to serious problems like obstructive sleep apnea, says Dr. Shalini Paruthi.
“I think we just have to really thoughtfully interpret the data we're getting from these and look for patterns because that can be really helpful,” said Paruthi, a sleep medicine physician and spokesperson for the American Academy...
FDA clears Vivos device for OSA
November 30, 2023HME News Staff
LITTLETON, Colo. – Vivos Therapeutics has received 510(k) clearance from the U.S. Food and Drug Administration for treating severe obstructive sleep apnea in adults using its removable CARE (Complete Airway Repositioning and/or Expansion) oral appliances. CARE appliances include the flagship DNA oral appliance, the mRNA oral appliance and the mmRNA oral appliance. “This achievement is a pivotal milestone for Vivos and elevates our proven treatment options right into the mainstream of...
Apnimed enters JV with Shionogi
November 20, 2023HME News Staff
CAMBRIDGE, Mass. – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacological therapies for the treatment of obstructive sleep apnea, has announced a joint venture with Shionogi & Co., a pharmaceutical company based in Japan, to develop therapies to treat OSA and other sleep disorders. The joint venture, Shionogi-Apnimed Sleep Science, combines Apnimed’s deep knowledge of OSA, highly experienced clinical-stage drug development team and robust network of...